Artelo Biosciences
ARTL0.723417.80% ( -0.1567 )
Artelo Biosciences (ARTL)
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the Unite...
- Open
- 0.8886
- High
- 0.9000
- Low
- 0.7052
- Prev. Close
- 0.8801
- Volume
- 282.06K
- Turnover
- 221.50K
- Avg Price
- 0.7853
- Bid/Ask Ratio
- --
- Amplitude
- 22.13%
- 52wk High
- 41.9700
- Volume Ratio
- 2.58
- Turnover Ratio
- 40.00%
Artelo Biosciences Analyst Rating
View MoreForecast & Rating
Nov 19, 2025Price forecast
$54.007364.75%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- Unusual Whales · Jul 22 at 07:41 AM
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
- PUBT · Jul 22 at 07:39 AM
Artelo analysis finds low-dose OTC CBD products miss therapeutic efficacy across 50-plus studies
- StockTitan · Jul 13 at 11:47 PM
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 | ARTL Stock News
- PUBT · Jul 13 at 08:28 AM
Artelo Biosciences reports positive preclinical data for ART27.13 in paclitaxel-induced peripheral neuropathy model
- Unusual Whales · Jul 1 at 07:44 AM
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
- PUBT · Jul 1 at 07:42 AM
Artelo Biosciences reports positive preclinical data for ART26.12 in spinal cord injury neuropathic pain model
